- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07583342
Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis
Open-label, Multicenter, Phase IV, Study Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis
The goal of this study is to learn if Relizorb, a fat-digesting enzyme, can improve tolerance of tube feeds in adult patients with moderate to severe pancreatitis. The main question it aims to answer is:
Does Relizorb allow more nutrition to be delivered to participants than they received without it?
Participants will be observed with standard, universal monitoring after adding Relizorb to their nutrition regimen.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
New York
-
Bay Shore, New York, Verenigde Staten, 11706
- South Shore University Hospital
-
Manhasset, New York, Verenigde Staten, 11030
- North Shore University Hospital
-
Manhattan, New York, Verenigde Staten, 10075
- Lenox Hill Hospital
-
New Hyde Park, New York, Verenigde Staten, 11040
- Long Island Jewish Medical Center
-
Staten Island, New York, Verenigde Staten, 10305
- Staten Island University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Male or female aged 18 + years of age
- Admission to the Surgical Intensive Care Unit in the Northwell Health hospital system
- Moderate to severe acute pancreatitis based on Atlanta criteria
- Inability to tolerate ≥75% of goal EN (25 kcal/kg/d)
Exclusion Criteria:
- Moribund patients expected to expire within 120 hours
- Evidence of unresolved intestinal obstruction, ischemia, bleeding, perforation, fistulas or tract discontinuity, or other contraindication for enteral nutrition
- Diagnosis or evidence of C. Difficile or other gastrointestinal infection that may manifest with diarrhea
- Pre-existing constipation defined as laxative or stool softener use prior to admission to the hospital
- Patients receiving cancer-related treatment in the last 3 months
- History of cystic fibrosis
- Any other reason that the treating or investigator team considers to be a contraindication to enteral nutrition
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Relizorb treatment
Patients with moderate to severe pancreatitis who are not tolerating sufficient enteral nutrition will have a lipase-containing cartridge (Relizorb) placed in-line with their enteral nutrition tubing, to digest the fat in the formula prior to entering the patient's intestine.
|
An in-line digestive enzyme cartridge designed for hydrolyzing lipids within enteral nutrition will be used to improve tube feed tolerance in patients with moderate to severe pancreatitis.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percent of goal nutrition delivered at 72 hours
Tijdsspanne: From enrollment to the end of treatment at 72 hours
|
Change from baseline in percentage of goal enteral nutrition (kcal/kg/day) received 3 days (72 hours) following initiation of RELiZORB.
Baseline is considered the 24 hours prior to RELiZORB start.
|
From enrollment to the end of treatment at 72 hours
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percent of goal nutrition delivered at 24 hours
Tijdsspanne: From enrollment to 24 hours after starting RELiZORB
|
Change from baseline in goal percentage of enteral nutrition (kcal/kg/day) received 1 day (24 hours) following initiation of RELiZORB.
|
From enrollment to 24 hours after starting RELiZORB
|
|
Responders at 72 hours
Tijdsspanne: From enrollment to end of treatment at 72 hours
|
Percent of patients considered responders defined as receiving ≥80% of their daily enteral nutritional goal 3 days (72 hours) following initiation of RELiZORB use.
|
From enrollment to end of treatment at 72 hours
|
|
Responders at 24 hours
Tijdsspanne: From enrollment to 24 hours after starting treatment
|
Percent of patients considered responders defined as receiving ≥80% of their daily enteral nutritional goal 1 day (24 hours) following initiation of RELiZORB use.
|
From enrollment to 24 hours after starting treatment
|
|
Vomiting
Tijdsspanne: From enrollment to completion of treatment at 72 hours
|
Change in the number of vomiting episodes per 24 hour period from baseline to 24 and 72 hours following initiation of RELiZORB use
|
From enrollment to completion of treatment at 72 hours
|
|
Stool volume
Tijdsspanne: From enrollment to completion of treatment at 72 hours
|
Change in stool volume per 24 hour period from baseline to 24 and 72 hours following initiation of RELiZORB use (if rectal tube is in place)
|
From enrollment to completion of treatment at 72 hours
|
|
Bowel movements
Tijdsspanne: From enrollment to completion of treatment at 72 hours
|
Change in number of bowel movement episodes in 24 hours from baseline to 24 hours and 72 hours after RELiZORB (if no rectal tube)
|
From enrollment to completion of treatment at 72 hours
|
|
Feeding Interruptions
Tijdsspanne: From enrollment to completion of treatment at 72 hours
|
Number of unplanned interruptions in tube feeding from baseline to 24 hours and 72 hours following initiation of RELiZORB use
|
From enrollment to completion of treatment at 72 hours
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Laura Hansen, MD, Northwell Health
- Hoofdonderzoeker: Rafael Barrera, MD, Northwell Health
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 25-0106-LIJ
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .